Wilder on New Heart Drugs in MM&M: Drug Makers Need to Proactively Share Information With Payers


In a new article appearing in the latest MM&M, Precision for Value EVP and Managing Partner Kelly Wilder shares her perspective on the challenges of marketing new heart drugs. Wilder says drug makers need to proactively share information with payers about which patients should be taking a drug—even if doing so may put them at risk of narrowing a product’s use to a smaller population. “It’s a hard conversation to have,” Wilder explains. “No one wants to be niche. You want the broadest access and to leave that decision to clinicians.”

To read the complete article, please click here.


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.